Literature DB >> 17371859

High-throughput mRNA profiling characterizes the expression of inflammatory molecules in sepsis caused by Burkholderia pseudomallei.

W Joost Wiersinga1, Mark C Dessing, Piet A Kager, Allen C Cheng, Direk Limmathurotsakul, Nicholas P Day, Arjen M Dondorp, Tom van der Poll, Sharon J Peacock.   

Abstract

Sepsis is characterized by an uncontrolled inflammatory response to invading microorganisms. We describe the inflammatory mRNA profiles in whole-blood leukocytes, monocytes, and granulocytes using a multigene system for 35 inflammatory markers that included pro- and anti-inflammatory cytokines, chemokines, and signal transduction molecules in a case-control study with 34 patients with sepsis caused by the gram-negative bacterium Burkholderia pseudomallei (the pathogen causing melioidosis) and 32 healthy volunteers. Relative to healthy controls, patients with sepsis showed increased transcription of a whole array of inflammatory genes in peripheral blood leukocytes, granulocytes, and monocytes. Specific monocyte and granulocyte mRNA profiles were identified. Strong correlations were found between inflammatory mRNA expression levels in monocytes and clinical outcome. These data underline the notion that circulating leukocytes are an important source for inflammatory mediators in patients with gram-negative sepsis. Gene profiling such as was done here provides an excellent tool to obtain insight into the extent of inflammation activation in patients with severe infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17371859      PMCID: PMC1932877          DOI: 10.1128/IAI.01733-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  23 in total

1.  Melioidosis: a clinical model for gram-negative sepsis.

Authors: 
Journal:  J Med Microbiol       Date:  2001-08       Impact factor: 2.472

2.  Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification.

Authors:  Jan P Schouten; Cathal J McElgunn; Raymond Waaijer; Danny Zwijnenburg; Filip Diepvens; Gerard Pals
Journal:  Nucleic Acids Res       Date:  2002-06-15       Impact factor: 16.971

3.  Toll-like receptor mRNA levels in alveolar macrophages after inhalation of endotoxin.

Authors:  N A Maris; M C Dessing; A F de Vos; P Bresser; J S van der Zee; H M Jansen; C A Spek; T van der Poll
Journal:  Eur Respir J       Date:  2006-09       Impact factor: 16.671

4.  Human macrophage activation programs induced by bacterial pathogens.

Authors:  Gerard J Nau; Joan F L Richmond; Ann Schlesinger; Ezra G Jennings; Eric S Lander; Richard A Young
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

5.  Efficacy and safety of recombinant human activated protein C for severe sepsis.

Authors:  G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

Review 6.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference.

Authors:  Mitchell M Levy; Mitchell P Fink; John C Marshall; Edward Abraham; Derek Angus; Deborah Cook; Jonathan Cohen; Steven M Opal; Jean-Louis Vincent; Graham Ramsay
Journal:  Crit Care Med       Date:  2003-04       Impact factor: 7.598

7.  Prognostic value of cytokine concentrations (tumor necrosis factor-alpha, interleukin-6, and interleukin-10) and clinical parameters in severe melioidosis.

Authors:  A J Simpson; M D Smith; G J Weverling; Y Suputtamongkol; B J Angus; W Chaowagul; N J White; S J van Deventer; J M Prins
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

Review 8.  Immunotherapy of sepsis.

Authors:  T van der Poll
Journal:  Lancet Infect Dis       Date:  2001-10       Impact factor: 25.071

Review 9.  The immunopathogenesis of sepsis.

Authors:  Jonathan Cohen
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

10.  Treatment with an anti-CD14 monoclonal antibody delays and inhibits lipopolysaccharide-induced gene expression in humans in vivo.

Authors:  C Arnold Spek; Annelies Verbon; Hella Aberson; John P Pribble; Cathal J McElgunn; Terence Turner; Tim Axtelle; Jan Schouten; Tom Van Der Poll; Pieter H Reitsma
Journal:  J Clin Immunol       Date:  2003-03       Impact factor: 8.317

View more
  29 in total

1.  Natural history of inhalation melioidosis in rhesus macaques (Macaca mulatta) and African green monkeys (Chlorocebus aethiops).

Authors:  John J Yeager; Paul Facemire; Paul A Dabisch; Camenzind G Robinson; David Nyakiti; Katie Beck; Reese Baker; M Louise M Pitt
Journal:  Infect Immun       Date:  2012-07-09       Impact factor: 3.441

2.  Role of Toll-Like Receptor 5 (TLR5) in Experimental Melioidosis.

Authors:  Emma Birnie; Tassili A F Weehuizen; Jacqueline M Lankelma; Hanna K de Jong; Gavin C K W Koh; Miriam H P van Lieshout; Joris J T H Roelofs; Andries E Budding; Alex F de Vos; Tom van der Poll; W Joost Wiersinga
Journal:  Infect Immun       Date:  2019-07-23       Impact factor: 3.441

3.  Burkholderia pseudomallei triggers altered inflammatory profiles in a whole-blood model of type 2 diabetes-melioidosis comorbidity.

Authors:  Jodie Morris; Natasha Williams; Catherine Rush; Brenda Govan; Kunwarjit Sangla; Robert Norton; Natkunam Ketheesan
Journal:  Infect Immun       Date:  2012-04-02       Impact factor: 3.441

4.  Development of reagents and assays for the detection of pathogenic Burkholderia species.

Authors:  Omar Qazi; Mridula Rani; Annie J Gnanam; Thomas W Cullen; Christopher M Stead; Haley Kensing; Kate McCaul; Sarah Ngugi; Joann L Prior; Alexandria Lipka; Judit M Nagy; C Whitlock Gregory; Barbara M Judy; Sarah V Harding; Richard W Titball; Sachdev S Sidhu; M Stephen Trent; G Barrie Kitto; Alfredo Torres; D Mark Estes; Brent Iverson; George Georgiou; Katherine A Brown
Journal:  Faraday Discuss       Date:  2011       Impact factor: 4.008

5.  In vivo endotoxin synchronizes and suppresses clock gene expression in human peripheral blood leukocytes.

Authors:  Beatrice Haimovich; Jacqueline Calvano; Adrian D Haimovich; Steve E Calvano; Susette M Coyle; Stephen F Lowry
Journal:  Crit Care Med       Date:  2010-03       Impact factor: 7.598

6.  Impaired early cytokine responses at the site of infection in a murine model of type 2 diabetes and melioidosis comorbidity.

Authors:  Kelly A Hodgson; Brenda L Govan; Anna K Walduck; Natkunam Ketheesan; Jodie L Morris
Journal:  Infect Immun       Date:  2012-12-03       Impact factor: 3.441

7.  Presymptomatic prediction of sepsis in intensive care unit patients.

Authors:  R A Lukaszewski; A M Yates; M C Jackson; K Swingler; J M Scherer; A J Simpson; P Sadler; P McQuillan; R W Titball; T J G Brooks; M J Pearce
Journal:  Clin Vaccine Immunol       Date:  2008-05-14

8.  Initial delay in the immune response to Francisella tularensis is followed by hypercytokinemia characteristic of severe sepsis and correlating with upregulation and release of damage-associated molecular patterns.

Authors:  Chris A Mares; Sandra S Ojeda; Elizabeth G Morris; Qun Li; Judy M Teale
Journal:  Infect Immun       Date:  2008-04-14       Impact factor: 3.441

Review 9.  Melioidosis.

Authors:  W Joost Wiersinga; Harjeet S Virk; Alfredo G Torres; Bart J Currie; Sharon J Peacock; David A B Dance; Direk Limmathurotsakul
Journal:  Nat Rev Dis Primers       Date:  2018-02-01       Impact factor: 52.329

10.  Expression and function of macrophage migration inhibitory factor (MIF) in melioidosis.

Authors:  W Joost Wiersinga; Thierry Calandra; Liesbeth M Kager; Gerritje J W van der Windt; Thierry Roger; Didier le Roy; Sandrine Florquin; Sharon J Peacock; Fred C G J Sweep; Tom van der Poll
Journal:  PLoS Negl Trop Dis       Date:  2010-02-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.